Retinoid differentiation therapy in promyelocytic leukemia.
Acute promyelocytic leukemia (APL) is a specific type of acute myeloid leukemia characterized by the morphology of the blast cells, a specific t(15;17) translocation, and risks of definite coagulopathy. Recently this leukemia was further characterized by an exquisite sensitivity to all-trans retinoic acid's differentiation effect and the production of a fusion gene altering the gene of RARalpha and a novel gene PML. In vivo differentiation therapy with retinoids in APL patients follows strict guidelines related both to the APL cell and the biodisposal of all-trans retinoic acid.
Chomienne
C
C
Hopital Saint-Louis, Institute of Hematology, Paris, France.
Fenaux
P
P
Degos
L
L
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002454:Cell Differentiation / Q000187:drug effects; D004351:Drug Resistance; D006801:Humans; D007536:Isomerism; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy* / Q000235:genetics; D009504:Neutrophils; D018168:Receptors, Retinoic Acid / Q000235:genetics / Q000378:metabolism; D012008:Recurrence; D014212:Tretinoin / Q000009:adverse effects / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D018168:Receptors, Retinoic Acid; D014212:Tretinoin